Recordati Extends Deadline and Lowers Threshold for Board of Statutory Auditors Slates

Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has provided an update.

Recordati has announced that, ahead of the Ordinary and Extraordinary Shareholders’ Meeting scheduled for 29 April 2026, only a single slate of candidates for the renewal of its Board of Statutory Auditors for the 2026–2028 term has been filed by majority shareholder Rossini S.àr.l. As a result, in line with Consob rules and the company’s by-laws, the deadline for submitting additional slates has been extended to 7 April 2026 at 6:00 p.m., and the minimum participation threshold for filing slates has been cut from 1% to 0.5% of the share capital with voting rights.

The company stated that any further slates submitted under the extended window, along with the majority slate already filed, will be made publicly available by 8 April 2026 through the usual regulatory channels. The move widens access for minority shareholders to put forward candidates for the Board of Statutory Auditors, potentially increasing governance participation and reinforcing transparency ahead of a new three-year oversight mandate for the company’s audit body.

The most recent analyst rating on (IT:REC) stock is a Buy with a EUR57.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.

More about Recordati Industria Chimica e Farmaceutica SPA

Recordati Industria Chimica e Farmaceutica S.p.A. is an international pharmaceutical group listed on Borsa Italiana, originating from a family-run pharmacy in Northern Italy in the 1920s. The company provides therapeutic options in both general and specialist medicine, as well as in the rare disease field, operating in around 150 countries across EMEA, the Americas and APAC with a fully integrated model from clinical development to API and finished product manufacturing, marketing and licensing.

Recordati employs more than 4,580 people worldwide and focuses on addressing the challenges of common and rare diseases under its purpose of “unlocking the full potential of life”. Its portfolio spans active pharmaceutical ingredients and finished pharmaceutical products, reflecting a strategy aimed at broad healthcare access and long-term presence in both mainstream and niche therapeutic markets.

Average Trading Volume: 372,629

Technical Sentiment Signal: Buy

Current Market Cap: €10.32B

For an in-depth examination of REC stock, go to TipRanks’ Overview page.